Stay updated on Sacituzumab Govitecan in mCRPC after 2nd Gen AR Clinical Trial

Sign up to get notified when there's something new on the Sacituzumab Govitecan in mCRPC after 2nd Gen AR Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Sacituzumab Govitecan in mCRPC after 2nd Gen AR Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The footer now displays site revision v3.8.0 instead of v3.7.2, while the study page still shows a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-31T13:46:31.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    A site-wide notice announces an NIH transition from using “Artificial Intelligence” to “Super Intelligence” terminology. The study record itself is not displayed.
    Difference
    1%
    Check dated 2026-10-24T15:24:32.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The record presents details of a Phase 2 study of sacituzumab govitecan for metastatic castration-resistant prostate cancer, including its treatment plan, eligibility criteria, outcome measures, and study locations. It also includes the study’s current status and record history.
    Difference
    50%
    Check dated 2026-10-17T15:14:41.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    The footer displays site revision v3.7.1 instead of v3.7.0. The study page continues to show a 403 error.
    Difference
    0.2%
    Check dated 2026-10-10T15:16:08.000Z thumbnail image
  5. Check
    43 days ago
    Change Detected
    Summary
    The study page now shows a 403 Forbidden error, replacing the usual study content and navigation. This makes the trial record inaccessible and blocks users from viewing the study details.
    Difference
    18%
    Check dated 2026-09-19T20:25:55.000Z thumbnail image
  6. Check
    50 days ago
    Change Detected
    Summary
    Added metadata entries: Prostate cancer; related topics: MedlinePlus Genetics. These additions connect the study to disease-focused and genetics-related indexing, improving discoverability for users exploring prostate cancer and genetics resources.
    Difference
    0.2%
    Check dated 2026-09-12T18:15:28.000Z thumbnail image

Stay in the know with updates to Sacituzumab Govitecan in mCRPC after 2nd Gen AR Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Sacituzumab Govitecan in mCRPC after 2nd Gen AR Clinical Trial page.